Glycosmedia

Diabetes News Service

Privacy & Cookies: This site uses cookies. By continuing to use this website, you agree to their use.
To find out more, including how to control cookies, see here: Cookies Policy
  • News
  • Archive
  • Categories & Tags
  • Journal Watch
  • Updates
  • Education
  • Reviews
  • About us ▼
    • About Glycosmedia
    • Editorial Team
    • Frequently asked questions
    • Comments
    • Press Releases
    • Disclaimer
  • Subscribe
  • Contact

Diabetes News

Tag: HbA1c


Glycemic control before admission is an important determinant of prognosis in patients with coronavirus disease 2019

November 25th 2020

HbA1c was an independent risk factor for poor outcomes in coronavirus disease 2019 patients. Severe pulmonary infection and consequent acute respiratory distress syndrome might be the primary causes of death in insufficient glycemic control patients (Journal of Diabetes Investigation)

Categories: News, Pathology
Tags: COVID-19, glycaemic control, HbA1c

Categories: Pathology
Tags: COVID-19, glycaemic control, HbA1c

Diabetes distress and HbA1c in racially/ethnically and socioeconomically diverse youth with type 1 diabetes

August 26th 2020

Diabetes distress is elevated in a younger population of children with T1D who are from racial/ethnic minority backgroundsor have markers of lower SES (Pediatric Diabetes)

Categories: News, Psychological
Tags: HbA1c, Type 1 Diabetes

Categories: Psychological
Tags: HbA1c, Type 1 Diabetes

Diabetes, Glycated Hemoglobin, and the Risk of Myocardial Infarction in Women and Men: A Prospective Cohort Study of the UK Biobank

July 14th 2020

Although the incidence of MI was higher in men than women, the presence of diabetes is associated with a greater excess relative risk of MI in women. However, each 1% higher HbA1c was associated with an 18% greater risk of MI in both women and men (Diabetes Care)

Categories: Cardiovascular, News
Tags: HbA1c, MI

Categories: Cardiovascular
Tags: HbA1c, MI

Sotagliflozin added to optimised insulin therapy leads to HbA1c reduction without weight gain in adults with type 1 diabetes

July 5th 2020

When added to optimised insulin therapy, sotagliflozin improved glycaemic control and body weight and enabled more adults with T1D to achieve A1c goals without weight gain over 52 weeks, although there was more DKA relative to placebo (Diabetes, Obesity and Metabolism)

Categories: Medication, News
Tags: HbA1c, insulin, sotagliflozin, Type 1 Diabetes

Categories: Medication
Tags: HbA1c, insulin, sotagliflozin, Type 1 Diabetes

Comparative effectiveness of dapagliflozin vs DPP ‐4 inhibitors on a composite endpoint of HbA1c , body weight, and blood pressure reduction in the real world

May 27th 2020

T2D patients initiating the SGLT2i dapagliflozin had a greater probability of attaining a composite endpoint of clinically relevant reductions in HbA1c, body weight and SBP, compared to similar patients initiating a DPP‐4i in the same period and healthcare setting (Diabetes/Metabolism Research and Reviews)

Categories: Medication, News
Tags: dapagliflozin, DPP‐4i, HbA1c, SGLT2 inhibitors, Type 2 Diabetes

Categories: Medication
Tags: dapagliflozin, DPP‐4i, HbA1c, SGLT2 inhibitors, Type 2 Diabetes

Prevalence of Microvascular and Macrovascular Disease in the Glycemia Reduction Approaches in Diabetes – A Comparative Effectiveness (GRADE) Study Cohort

May 24th 2020

In the GRADE cohort with <10 years of T2D and a mean HbA1c of 8.0%, diabetes complications were present in a substantial fraction of participants, more so than might otherwise have been expected (Diabetes Research and Clinical Practice)

Categories: Cardiovascular, News
Tags: HbA1c, Type 2 Diabetes

Categories: Cardiovascular
Tags: HbA1c, Type 2 Diabetes

Episodes of severe hypoglycemia is associated with a progressive increase in hemoglobin A1c in children and adolescents with type 1 diabetes

April 19th 2020

Severe hypoglycemia was followed by a progressive and lasting increase in HbA1c among Danish children and adolescents with T1D. Thus, in addition to the known risk of new episodes of hypoglycemia and cognitive impairment, SH contributes to long‐term diabetes complications (Pediatric Diabetes)

Categories: News, Pathology
Tags: HbA1c, hypoglycemia, Type 1 Diabetes

Categories: Pathology
Tags: HbA1c, hypoglycemia, Type 1 Diabetes

Effect of Hemoglobin A1c Reduction or Weight Reduction on Blood Pressure in Glucagon‐Like Peptide‐1 Receptor Agonist and Sodium‐Glucose Cotransporter‐2 Inhibitor Treatment in Type 2 Diabetes Mellitus

April 2nd 2020

Treatment with GLP‐1RA and SGLT2i led to significant reductions in BP in patients with type 2 diabetes mellitus. Weight reduction was significantly and independently associated with BP reductions in GLP‐1RA treatment and SGLT2i treatment (JAHA)

Categories: Hypertension, News
Tags: GLP‐1RA, HbA1c, SGLT2i

Categories: Hypertension
Tags: GLP‐1RA, HbA1c, SGLT2i

Prognostic Significance of Long-term HbA1c Variability for All-Cause Mortality in the ACCORD Trial

April 2nd 2020

Long-term visit-to-visit HbA1c variability was a strong predictor of all-cause mortality. HbA1c VIM combined with HbA1c mean conferred an increased risk for all-cause mortality in the intensive-therapy group (Diabetes Care)

Categories: Pathology
Tags: ACCORD, HbA1c

Retinopathy develops at similar glucose levels but higher HbA1c levels in people with black African ancestry compared to white European ancestry: evidence for the need to individualize HbA1c interpretation

March 4th 2020

Since retinopathy occurs at higher HbA1c levels in black people for a given level of average plasma glucose, strategies may be needed to individualize the interpretation of HbA1c measurements (Diabetic Medicine)

Categories: News, Ophthalmology
Tags: HbA1c

Categories: Ophthalmology
Tags: HbA1c

The Relationship between Self‐Monitored Blood Glucose Values and Glycated haemoglobin in Insulin‐treated Patients with Type 2 Diabetes

February 2nd 2020

These data provide patients and clinicians information on the relationship between HbA1c and SMBG measurements in patients with type 2 DM, and support the value of frequent blood glucose measurements for assessing overall glycaemic control (Diabetic Medicine)

Categories: Monitoring, News
Tags: HbA1c, SMBG, Type 2 Diabetes

Categories: Monitoring
Tags: HbA1c, SMBG, Type 2 Diabetes

Effect of mean HbA1c on the association of HbA1c variability and all‐cause mortality in patients with type 2 diabetes mellitus

January 6th 2020

Mean HbA1c contributed to the correlation between HbA1c variability and all‐cause mortality. The risks associated with HbA1c variability and glycemic control status were similar. The relationship between mean HbA1c and mortality presented a J‐shaped distribution for both low and high HbA1c variability (Diabetes, Obesity and Metabolism)

Categories: Monitoring, News
Tags: HbA1c, Type 2 Diabetes

Categories: Monitoring
Tags: HbA1c, Type 2 Diabetes

A review of the NG17 recommendations for the use of basal insulin in type 1 diabetes

November 22nd 2019

Many of the trials used in this analysis were treat‐to‐target, which minimize differences in HbA1c. In the NMAs, statistical significance was severely undermined by the wide credible intervals. Despite these limitations, point estimates of HbA1c were used to rank the insulins and formed the basis of NG17 guidance. This study queries whether such analyses should be used to make specific clinical recommendations (Diabetic Medicine)

Categories: Monitoring, News
Tags: HbA1c, insulin, Type 1 Diabetes

Categories: Monitoring
Tags: HbA1c, insulin, Type 1 Diabetes

Sleep and HbA1c in Patients With Type 2 Diabetes: Which Sleep Characteristics Matter Most?

November 14th 2019

Sleep in general may be a modifiable factor of importance for patients with T2D. The prevention of sleep curtailment may serve as a primary focus in the sleep-centered management of T2D (Diabetes Care)

Categories: News, Treatment
Tags: HbA1c, sleep, Type 2 Diabetes

Categories: Treatment
Tags: HbA1c, sleep, Type 2 Diabetes

Benefits and harms of intensive glycemic control in patients with type 2 diabetes

November 6th 2019

Delivering evidence based, patient centered care to people with type 2 diabetes requires a paradigm shift and departure from the predominantly glucocentric view of diabetes management. Instead of prioritizing intensive glycemic control, the focus needs to be on ensuring access to adequate diabetes care (BMJ)

Categories: Management, News
Tags: HbA1c, Type 2 Diabetes

Categories: Management
Tags: HbA1c, Type 2 Diabetes

Variation in the achievement of HbA1c, blood pressure and LDL cholesterol targets in type 2 diabetes in general practice and characteristics associated with risk factor control

November 3rd 2019

Clinical diabetes management is difficult, and few people meet all three risk factor control targets. The proportion of people reaching target varied among general practitioners and practices. Several population, general practitioner and practice characteristics only explained a small part of the total variation (Diabetic Medicine)

Categories: News, Treatment
Tags: HbA1c, LDL, Type 2 Diabetes

Categories: Treatment
Tags: HbA1c, LDL, Type 2 Diabetes

Variability in Glycated Hemoglobin and Risk of Poor Outcomes Among People With Type 2 Diabetes in a Large Primary Care Cohort Study

October 23rd 2019

HbA1c variability was strongly associated with overall mortality and emergency hospitalization and not explained by average HbA1c or hypoglycemic episodes. Only for CAD and IS hospitalizations was no association found, with average HbA1c strongly predictive. Targets should focus on both stability and absolute level of HbA1c (Diabetes Care)

Categories: News, Pathology
Tags: HbA1c, Type 2 Diabetes

Categories: Pathology
Tags: HbA1c, Type 2 Diabetes

HbA1c level as a risk factor for retinopathy and nephropathy in children and adults with type 1 diabetes: Swedish population based cohort study

August 29th 2019

Risk of retinopathy and nephropathy did not differ at HbA1c levels <6.5% but increased for severe hypoglycaemia compared with HbA1c levels 6.5-6.9%. The risk for severe complications mainly occurred at HbA1c levels >8.6%, but for milder complications was increased at HbA1c levels >7.0% (BMJ)

Categories: News, Pathology
Tags: HbA1c, Type 1 Diabetes

Categories: Pathology
Tags: HbA1c, Type 1 Diabetes

Distinct trajectories of HbA1c in newly diagnosed Type 2 diabetes from the DPV registry using a longitudinal group‐based modelling approach

August 11th 2019

Four subgroups with distinct HbA1c trajectories were determined in newly diagnosed Type 2 diabetes using a group‐based modelling approach. Approximately one‐third of people with newly diagnosed Type 2 diabetes need either better medication adherence or earlier intensification of glucose‐lowering therapy (Diabetic Medicine)

Categories: News, Pathology
Tags: HbA1c, Type 2 Diabetes

Categories: Pathology
Tags: HbA1c, Type 2 Diabetes

Adjunct Therapy in Type 1 Diabetes: A Survey to Uncover Unmet Needs and Patient Preferences Beyond HbA1c Measures

May 17th 2019

This survey highlights the importance of measures beyond HbA1c, such as treatment simplification and TIR, and patient preference for adjunct therapies that help address unmet needs in type 1 diabetes treatment (Diabetes Technology and Therapeutics)

Categories: News, Treatment
Tags: HbA1c, Type 1 Diabetes

Categories: Treatment
Tags: HbA1c, Type 1 Diabetes
  • 1
  • 2
  • 3
  • …
  • 6
  • Next Page »

Subscribe

subscribe-iconFREE weekly updates by email Please CLICK HERE

Platinum Sponsors

Boehringer Ingelheim Lilly

Gold Sponsors

Sanofi DiabetesAstraZenecaNapp DiabetesNovo Nordisk

Silver Sponsors

AmgenWelsh Endocrinology and Diabetes Society (WEDS)Abbott Diabetes Care

FUNDING NOTICE

The Glycosmedia website and newsletter has been made possible with funding support from our sponsors. None of our sponsors have control over the content of the website, newsletter, apps, Twitter feed or RSS newsfeed.

For information about sponsorship and advertising please contact our editor-in-chief Jim Young jim@glycosmedia.com

Advertisers

CRC Press

The organisations advertising in this section do not have any input into, or editorial control over the content of this website.

Categories

  • Audits
  • Bariatric
  • Biochemistry
  • Cardiovascular
  • Devices
  • Diagnosis
  • Diet
  • Education
  • Epidemiology
  • Genetics
  • Gestational
  • Guidance
  • Guidelines
  • Hepatology
  • Hypertension
  • Immunology
  • Management
  • Media
  • Medication
  • Meetings
  • Monitoring
  • Nephrology
  • Neuropathy
  • Nephropathy
  • Obesity
  • Ophthalmology
  • Paediatrics
  • Pathology
  • Pharma
  • Pharmacology
  • Physiology
  • Podiatry
  • Prediabetes
  • Prevalence
  • Prevention
  • Psychological
  • Reports
  • Research
  • Screening
  • Sponsorship
  • Technology
  • Testing
  • Transplantation
  • Treatment
  • Wound Care

To see all articles associated with a category just click on the category name.

Popular Tags

ADA BMI canagliflozin CGM CKD closed-loop COVID-19 dapagliflozin DPP4 Empagliflozin exenatide GLP1 glycaemic control HbA1c heart failure hyperglycemia hypoglycemia incretin insulin insulin pump Insulin resistance Ketoacidosis lada liraglutide metformin microvascular mortality NAFLD NICE pioglitazone retinopathy semaglutide SGLT2 inhibitors sitagliptin statin sulfonylureas Type 1 Diabetes Type 2 Diabetes USA Vitamin D

To see all articles associated with a tag just click on the tag name.

Complete list of Tags ››

Join us on Facebook

Join us on Facebook

Please share Glycosmedia:

Follow us on Twitter

My Tweets

mobileGlycosmedia is also available as an App:

For iPhone and iPad | For Android devices


Sponsorship and Advertising

For information about sponsorship and advertising please contact our editor-in-chief Jim Young jim@glycosmedia.com

Copyright © 2021 Glycosmedia Partnership